Michiels Yves, Bugnon Olivier, Michiels Jean-François, Mazellier Sophie
Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
Community Pharmacy Unit, Pharmaceutical Sciences section, Universities of Geneva and Lausanne, Geneva, Switzerland.
BMJ Case Rep. 2019 Apr 29;12(4):e227951. doi: 10.1136/bcr-2018-227951.
In addition to the TRANSFORMS, FREEDOMS, INFORMS studies, very few publications have identified new cases of skin cancer in patients treated with fingolimod. Here, we present the case of a 52-year-old Caucasian patient with relapsing remitting multiple sclerosis for 19 years, with a phototype II with blue eyes, light brown hair, no personal or family history of melanoma and a low number of naevi (<10). She did not experience intense sun exposure in childhood as well as severe sunburn and did not practise sessions in ultraviolet cabins. This case is distinguished from other published cases, usually superficial spreading malignant melanoma by its unclassifiable histological character. The occurrence of skin cancers in patients with multiple sclerosis remains exceptional, but new cases have recently emerged requiring the strengthening of dermatological follow-up of such patients.
除了TRANSFORMS、FREEDOMS、INFORMS研究外，很少有出版物报道在用芬戈莫德治疗的患者中发现皮肤癌新病例。在此，我们报告一例52岁的白种女性患者，患有复发缓解型多发性硬化症19年，皮肤光类型为II型，蓝眼睛，浅棕色头发，无黑色素瘤个人史或家族史，痣数量较少（<10个）。她童年时没有长时间暴露在阳光下，也没有严重晒伤，也没有使用过紫外线舱。该病例与其他已发表的病例不同，其组织学特征无法分类，通常为浅表扩散性恶性黑色素瘤。多发性硬化症患者发生皮肤癌的情况仍然罕见，但最近出现了新病例，需要加强对此类患者的皮肤科随访。
